Afamelanotide vs Melanotan II
Both Afamelanotide and Melanotan II are used for skin. Here's how their evidence, dosing, and regulatory status actually compare.
Afamelanotide
Evidence AAfamelanotide (Scenesse)
An FDA-approved selective MC1R agonist used to increase eumelanin density in erythropoietic protoporphyria patients. Off-label cosmetic tanning use is widespread internationally.
View full Afamelanotide profile →Melanotan II
Evidence C+Melanotan II (MT-II)
A non-selective melanocortin agonist (MC1R/MC3R/MC4R) that produces tanning and erection effects. Significant safety concerns including melanoma case reports.
View full Melanotan II profile →Side-by-Side
| Attribute | Afamelanotide | Melanotan II |
|---|---|---|
| Evidence Grade | A | C+ |
| FDA Status | FDA-approved (2019) for erythropoietic protoporphyria (EPP) | Not FDA-approved — sold illegally as cosmetic; FDA warning letters issued |
| Typical Dose | 16 mg subcutaneous implant every 2 months (clinical use) | 0.25–1 mg daily during loading, then maintenance (subcutaneous) |
| Clinics Indexed | 14 | 18 |
| Categories | skin | skin, sexual-health |
Key reported benefits — Afamelanotide
- ✓MC1R-selective tanning
- ✓FDA-approved for EPP
Key reported benefits — Melanotan II
- ✓UV-independent tanning
- ✓Erectile effect (off-label)
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.